Doxazosin - Isotope Labelled Standards
References
FAQ's
References
- Campbell, Simon Fraser, Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines, Pfizer Corp., Panama, US4188390A, February 12, 1980
- Cowlishaw, M. G.; Sharman, J. R., Doxazosin determination by high-performance liquid chromatography using fluorescence detection, Journal of Chromatography, Biomedical Applications, Volume: 344, Pages: 403-7, 1985
Frequently Asked Questions
What are the potential sources of impurities in Doxazosin?
The potential sources of impurities in Doxazosin include raw materials, reagents, solvents, and reaction intermediates used in the manufacturing process.
Can Doxazosin impurities affect the effectiveness of the medication?
Depending on the nature and concentration, impurities in Doxazosin can affect the drug's efficacy, stability, and safety.
What steps help ensure the control of Doxazosin impurities during drug development?
During drug development, extensive studies help identify and characterize impurities in Doxazosin, establish acceptable limits, and implement suitable control strategies.
What are the temperature conditions required to store Doxazosin impurities?
The recommended temperature for storing impurities in Doxazosin is a controlled room temperature, typically between 2-8 °C. Alternatively, the specific temperature indicated on the Certificate of Analysis (CoA) is required for proper storage.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.